Abbonarsi

The effect of antifibrinolytic agents in periacetabular osteotomy: A systematic review and meta-analysis - 12/06/22

Doi : 10.1016/j.otsr.2022.103271 
Chul-Ho Kim a, Eic Ju Lim b, Siyeon Kim c, Ji Wan Kim d,
a Department of Orthopedic Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 
b Department of Orthopedic Surgery, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea 
c Department of Orthopedic Surgery, Gachon University Gil Medical Center, 21, Namdong-daero 774 beon-gil, Namdong-gu, Incheon, Republic of Korea 
d Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro, 43-gil, Songpa-gu, Seoul, Republic of Korea 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

Periacetabular osteotomy (PAO) is a major hip preservation surgery for developmental dysplasia of the hip. It is inevitably associated with significant blood loss, so it requires frequent transfusions and could be a cause of perioperative morbidity. However, to date, a large number of studies has not evaluated the effect of antifibrinolytic agents in PAO. Therefore we performed a systematic review and meta-analysis to assess if antifibrinolytics would be effective in reducing blood loss and transfusion rate after PAO surgery.

Methods

In this systematic review and meta-analysis, MEDLINE, Embase, and Cochrane Library databases were systematically searched for studies published before April 4, 2020, that investigated the effect of antifibrinolytic agents in PAO. A pooled analysis was designed to identify differences between antifibrinolytic and control groups focusing on blood loss, transfusion, operation time, postoperative venous thromboembolism (VTE), and length of hospital stay.

Results

We included five studies involving 507 patients (antifibrinolytic group: 256; control group: 251). The pooled analysis showed that the control group had a greater total estimated blood loss (EBL) than the antifibrinolytic group (mean difference [MD]=−257.60mL, 95% confidence interval [CI] −389.68 to −125.53, p=0.0001), but there were no statistical differences in intraoperative EBL (MD=−46.46mL, 95% CI: −192.57 to 99.64, p=0.53). The allogenic transfusion rate was higher in the control group than in the antifibrinolytic group (odds ratio [OR] 0.21, 95% CI: 0.10–0.43, p<0.0001), but there was no difference in the autogenic transfusion rate (OR 0.35, 95% CI: 0.09–1.43, p=0.14). The pooled result showed no difference in operation time (MD=9.13min, 95% CI: −8.54 to 26.80, p=0.31). For the VTE rate, a pooled analysis was not conducted due to the lack of data. The length of hospital stay showed no differences (MD=−0.51 days, 95% CI: −1.17 to 0.16, p=0.13).

Conclusions

Antifibrinolytic use in PAO has positive effects in terms of reduced total EBL and allogenic transfusion rate.

Level of evidence

III; meta-analysis.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Antifibrinolytics, Antifibrinolytic agent, Tranexamic acid, Epsilon-aminocaproic acid, Periacetabular osteotomy, Meta-analysis


Mappa


© 2022  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 108 - N° 4

Articolo 103271- Giugno 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Hip survivorship following the Bernese periacetabular osteotomy for the treatment of acetabular dysplasia: A systematic review and meta-analysis
  • Joelle Hwee Inn Tan, Si Heng Sharon Tan, Meetrra Seyher Rajoo, Andrew Kean Seng Lim, James Hoipo Hui
| Articolo seguente Articolo seguente
  • Do the outcomes of hip arthroscopy for femoroacetabular impingement change over time?
  • Patrick G. Robinson, Helen Lu, Tom Williamson, Julian F. Maempel, Iain Murray, Deborah J. MacDonald, David F. Hamilton, Paul Gaston

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.